The Seattle-based medtech startup Proprio expects the Food and Drug Administration to approve its AR-platform Paradigm in H1 2023.
The six-year-old startup's Paradigm technology can improve surgery outcomes by helping surgeons identify where to insert incisions and place hardware.
More:
- Following its approval, the company plans to commercially launch the program.
- Paradigm uses high-def imaging technology to capture the operating room from above.
- It then uses AI and augmented reality to combine those images with pre-surgery 3D imaging.
- These images then guide the doctor through surgery.
- Proprio has several technology partners, including Intel, HTC, NVIDIA, Samsung, and the Paul G. Allen School of Computer Science at the University of Washington.
